BlackRock Amends ALNYLAM PHARMACEUTICALS Stake (SC 13G/A)
Ticker: ALNY · Form: SC 13G/A · Filed: Jan 26, 2024 · CIK: 1178670
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, passive-investment, amendment, pharmaceuticals
TL;DR
**BlackRock updated its passive stake in Alnylam Pharmaceuticals.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 26, 2024, indicating a change in its ownership of ALNYLAM PHARMACEUTICALS, INC. common stock as of December 31, 2023. This filing, Amendment No. 7, shows BlackRock's updated passive investment stake in the pharmaceutical company. This matters to investors because BlackRock is a major institutional investor, and changes in its holdings can signal shifts in its confidence or strategy regarding ALNYLAM PHARMACEUTICALS, INC.
Why It Matters
This filing updates BlackRock's passive ownership in Alnylam, providing transparency on a major institutional investor's position, which can influence market perception and trading decisions.
Risk Assessment
Risk Level: low — This is a routine update from a passive institutional investor and does not indicate any immediate significant risk or opportunity.
Analyst Insight
Investors should note BlackRock's continued passive interest in Alnylam Pharmaceuticals, but this filing alone doesn't suggest a need for immediate action, as it's a routine update of a passive stake.
Key Players & Entities
- BlackRock Inc. (company) — the entity filing the SC 13G/A, reporting its ownership in Alnylam Pharmaceuticals, Inc.
- ALNYLAM PHARMACEUTICALS, INC. (company) — the subject company whose common stock is being reported on
- December 31, 2023 (date) — the date of the event which required the filing of this statement
- January 26, 2024 (date) — the date the SC 13G/A was filed
- Amendment No: 7 (number) — the specific amendment number for this filing
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, filed under the Securities Exchange Act of 1934.
Who is the filer of this SC 13G/A?
The filer of this SC 13G/A is BlackRock Inc., a security brokers, dealers & flotation company based in New York, NY.
What company's securities are the subject of this filing?
The subject company is ALNYLAM PHARMACEUTICALS, INC., a pharmaceutical preparations company based in Cambridge, MA.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023.
What rule is BlackRock Inc. filing under for this Schedule 13G?
BlackRock Inc. is filing under Rule 13d-1(b), as indicated by the 'X' in the appropriate box.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 26, 2024 regarding ALNYLAM PHARMACEUTICALS, INC. (ALNY).